Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06324071
Other study ID # 2022_TSOD_125
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 8, 2024
Est. completion date April 2025

Study information

Verified date March 2024
Source Fitoplancton Marino, S.L.
Contact Carlos Infante
Phone +34 956561079
Email carlos.infante@easyalgae.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TetraSOD® is a unique marine phytoplankton (Tetraselmis chuii) SOD-rich ingredient that is grown under patent-protected technology exclusively designed by the company Fitoplancton Marino, S.L. (Spain). In a previous pilot trial, the ability of TetraSOD® (dose: 250 mg/day) to improve semen characteristics in idiopathic infertile men after three months of treatment was assessed, revealing significant improvements in almost all of the analyzed parameters. In a further clinical trial close to finish (ClinicalTrials.gov Identifier: NCT04864314) using the same dose, such positive results have been tested again in a higher number of patients, and additional parameters have been included in order to gain insights into the sperm physiological changes that underpin the improvement in semen quality. In this new clinical trial, an intermediate dose (125 mg/day) is going to be tested in an attempt to determine a range of TetraSOD® dosage being clinically active for the treatment of male infertility.


Description:

Infertility is an increasing global public health problem present in about 15-20% of the population of reproductive age, affecting as many as 186 million people worldwide. A male factor is present in approximately 50% of the infertile couples, a large number of them of unknown or idiopathic origin. Spermatogenesis is a complex biological process that requires a highly regulated genetic and hormonal program in a singular environment created by the interaction with different cell types to orchestrate a successful differentiation process. This process occurs periodically every 72 days during a man's fertile life. It has been demonstrated that semen quality is deteriorating over the time, perhaps as a result of exposition to several environmental factors related with lifestyle: drug use (such us tobacco, alcohol, marijuana, cocaine, opioids and anabolic agents), diet and overweight, disorders of the sleep-wake cycle and working conditions (continuous exposition to heat sources or toxic substances) that could impact both directly and indirectly on the complex process of spermatogenesis. Currently, the impact of oxidative stress, a cellular state product of an imbalance between the generation of highly unstable molecules known as reactive oxygen species (ROS) and the antioxidant cellular capacity in male fertility is being deeply investigated. High levels of oxidative stress in semen have been associated with both lower sperm concentration, sperm motility and acrosome integrity and higher sperm DNA damage and mitochondrial activity. Recent clinical trials have demonstrated the high prevalence of sperm DNA damage by up to 80% of men diagnosed with idiopathic male infertility. This DNA damage produced during spermatogenesis or sperm maturation process could be the result of an increase of reactive oxygen species (ROS) in male reproductive tract, which are related to different known factors (chronic systemic disease, use of some drugs, radiation or pesticides, febrile processes, old age and environmental factors related to lifestyle: smoking, obesity, alcohol) and other unknown so far. Antioxidant supplementation has gained relevance within routine practices in patients with reproductive problems. Different studies have shown the beneficial effect of antioxidant consumption against oxidative damage caused by environmental and pathological components, improving sperm characteristics associated with the seminal analysis. There are scientific evidences about the improvement of male fertility and higher rates of live newborn after antioxidant treatment in subfertile men. TetraSOD® is a unique commercial product comprised of 100% lyophilized biomass of the marine microalgae Tetraselmis chuii strain CCFM03, which is currently marketed for food and nutraceutical applications around the world by the company Fitoplancton Marino, S.L. This microalgae product is characterized by a high content in the antioxidant enzyme superoxide dismutase (SOD), as it is produced using own (patent pending) technology developed by the company. Results of in vitro studies with human cell lines suggest that TetraSOD® stimulates the cellular protective mechanisms against oxidative stress. Moreover, results previously obtained in a pilot study with the highest dose of TetraSOD® (250 mg/day) were promising, since a high statistically significant response was observed in three of the four studied parameters after three months of treatment. Taking into account these results, a new extended double-blind randomized and placebo-controlled clinical study has been performed to confirm the positive effects of dietary supplementation with 250 mg of TetraSOD® during 3 months (corresponding to the time of a complete spermatogenic cycle) in sperm quality. The main objective of this new study is to check the usefulness of a lower dose of TetraSOD® (125 mg/day) in the improvement of sperm quality, including sperm DNA fragmentation. As previously mentioned, oxidative stress is one of the main causes of sperm DNA damage. Nowadays, a diagnostic test for the study of the sperm DNA fragmentation exists, but it requires a specific sperm sample processing and the results are obtained in delay-time. In this new trial, correlation between sperm DNA fragmentation and static oxidation reduction potential (sORP) degree by the use of the Male Infertility Oxidative System (MiOXSYS) will be also tested as in the previous one with a higher dose of TetraSOD® (250 mg/day). Classical seminal parameters (semen volume, sperm concentration and number, sperm progressive motility) will be also quantified. In that way, with this new trial it will be possible to determine a range of TetraSOD® dosage being clinically active for the treatment of male infertility.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date April 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Age: 18 to 45 - Male patients with idiopathic infertility classified with asthenozoospermia, oligozoospermia or oligoasthenozoospermia after seminal assessment. - Not achieving pregnancy after at least one year of intercourse with the same partner without protective measures Exclusion Criteria: - Azoospermia (absence of spermatozoa) or severe oligozoospermia (< 5 x 10^6 spermatozoa/ml of ejaculate) - Testicular torsion or prostatitis - Urinary retention and infections - Drug consumption - Hormone treatments - Recent surgical interventions - Diabetes - Kidney or liver disease - Leukocytosis - Antioxidant supplement consumption in the last 3 months - BMI>30 Kg/m2 - Endocrinopathies, hypo and hyperthyroidism - Chromosomal anomalies (XX, XYY, XXY) - Treatments with anticoagulants - Radiotherapy/Chemotherapy - Participation in another clinical study prior to inclusion in this study that could affect the objectives of the current study

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Sham
Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days.
Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity
Participants in the Experimental group will receive a daily dose of 125 mg of TetraSOD® in a capsule during 90 days.

Locations

Country Name City State
Spain Hospital Clinic Barcelona

Sponsors (3)

Lead Sponsor Collaborator
Fitoplancton Marino, S.L. Fertypharm, Fundacio Clinic Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sperm motility Sperm motility will be assessed according to the method described in the World Health Organization (WHO) laboratory manual for the examination and processing of human semen, 5th ed. Geneva: World Health Organization (2010) 90 days
Primary Sperm concentration Sperm concentration will be determined according to the method described in the WHO laboratory manual for the examination and processing of human semen, 5th ed. Geneva: World Health Organization (2010) 90 days
Primary Sperm oxidative stress Sperm ROS intracellular will be measured by flow cytometry evaluating the sperm intracellular ROS (superoxide anion, hydroxyl radical, hydrogen peroxide) 90 days
Secondary DNA integrity DNA integrity/fragmentation will be evaluated using the COMET assay 90 days
Secondary sORP by MiOXSYS sORP will be also assessed using the MiOXSYS system 90 days
Secondary Adverse effects Any kind of adverse event attributable to TetraSOD® will be recorded during the duration of the trial 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05503862 - Home Semen Testing in Men Beginning Attempts to Conceive N/A
Recruiting NCT03307655 - Relationship Between Nitric Oxide (NO) in Follicular Fluid and Sperm Fertilization Ability N/A
Withdrawn NCT02839447 - A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0
Completed NCT00975117 - Spermotrend in the Treatment of Male Infertility Phase 3
Completed NCT00756561 - HOP-2A - Intratesticular Hormone Levels N/A
Recruiting NCT04541459 - Validation of New Devices Against Ambient Electromagnetic Radiation Early Phase 1
Completed NCT02889341 - Valuation of Variable Dose of Docosahexanoic Acid for the Improvement of the Parameters of Male Fertility N/A
Not yet recruiting NCT03167008 - Vitamin D Level vs Semen Parameters
Completed NCT02268123 - Correlating In Vitro Fertilization Outcomes After Euploid Blastocyst Transfer With Sperm DNA Fragmentation
Completed NCT01232465 - Impact of Sperm DNA Integrity on In Vitro Cycles N/A
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Completed NCT03552081 - Tobacco and Sperm Genome: Effects of Smoking Cessation N/A
Recruiting NCT05200663 - Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility Phase 2
Completed NCT02025270 - MSCs For Treatment of Azoospermic Patients Phase 1/Phase 2
Recruiting NCT06147700 - Identifying Molecular Determinants of Infertility in Men (MODIFY)
Recruiting NCT06188936 - Home Semen Analysis Tests as a Screening Tool for Fertility Patients N/A
Recruiting NCT04200118 - Epigenetic and Genetic Effects in Cancer Patients: Analysis Pre and After Treatment
Terminated NCT02605070 - Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia Phase 3
Completed NCT01407432 - Impact of Folates in the Care of the Male Infertility Phase 3
Completed NCT00596739 - A Study of the Pre- and Post-operative Semen Analyses and Reproductive Hormone Levels of Men Undergoing Weight-reduction Surgery N/A